RxDoctor Payments Data

Gary Wiltz, MD

Internal Medicine · Franklin, LANPI 1477596351

Payments from drug & device makers

$583in general payments, 2019–2025

Across 33 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$117
  • Exact Sciences$113
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$90
  • Vanda Pharmaceuticals Inc.$61
  • Pfizer$56
  • Axsome Therapeutics, Inc.$35
  • plus $110 from 6 others

What the payments were for

  • Food & beverage$583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$583 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,316
Medicare patients
35
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$167,739
FarxigaDapagliflozin Propanediol49$57,639
JanuviaSitagliptin Phosphate42$49,686
JardianceEmpagliflozin44$45,256
EliquisApixaban40$41,545
TradjentaLinagliptin26$28,004
MyrbetriqMirabegron30$23,206
EntrestoSacubitril/Valsartan21$21,370
Breo ElliptaFluticasone/Vilanterol33$18,926
TrulicityDulaglutide13$15,079
Clonidine70$12,126
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$7,946
SymbicortBudesonide/Formoterol Fumarate22$7,748
Levemir FlexpenInsulin Detemir14$4,620
Lidocaine52$3,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$12$73,26070 claims
PfizerEliquis$56$41,54540 claims
NovartisEntresto$19$21,37021 claims
AbbVieSynthroid$19$3,16029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Franklin

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →